Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InvaplexAR-Detox Vaccine for Shigella in Healthy Adults
NCT05961059Phase 1Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of InvaplexAR-Detox in shigellosis (5 arms), sponsored by Leiden University Medical Center. Primary endpoints: Occurrence of solicited adverse events and Occurrence of unsolicited adverse events. Started Oct 2024; status: recruiting.
02
Drugs
InvaplexAR-Detox
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT05961059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961059.